搜索
Palvella Therapeutics Inc
PVLA添加自选
114.240USD
-4.730-3.98%
收盘 05/15, 16:00（美东）报价延迟15分钟
1.64B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.98%
5天
-5.81%
1月
-11.19%
6月
+36.45%
今年开始到现在
+9.14%
1年
+428.64%
TradingKey Palvella Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Palvella Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名68/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价228.47。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Palvella Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Palvella Therapeutics Inc亮点
亮点风险
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-27.40，处于3年历史低位
机构加仓
最新机构持股11.89M股，环比增加11.46%
查克·罗伊斯持仓
明星投资者查克·罗伊斯持仓，最新持仓市值31.51K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.27
分析师目标
根据
17
位分析师
买入
评级
228.471
目标均价
+89.49%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Palvella Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Palvella Therapeutics Inc简介
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
公司代码PVLA
公司Palvella Therapeutics Inc
CEOKaupinen (Wesley H)
网址https://palvellatx.com/
相关品种
